- $1.70bn
- $962.97m
- $1.14m
- 51
- 14
- 14
- 15
Annual balance sheet for CG Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 53.6 | 143 | 188 | 742 |
| Net Total Receivables | 0.002 | 0.303 | 0.092 | 0.781 |
| Prepaid Expenses | ||||
| Total Current Assets | 58.4 | 147 | 194 | 754 |
| Net Property, Plant And Equipment | 0.2 | 0.506 | 0.491 | 0.493 |
| Other Long Term Assets | ||||
| Total Assets | 58.7 | 148 | 199 | 755 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 5.97 | 15.4 | 14.3 | 21.4 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 18.4 | 22.6 | 14.5 | 21.4 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 40.3 | 125 | 185 | 733 |
| Total Liabilities & Shareholders' Equity | 58.7 | 148 | 199 | 755 |
| Total Common Shares Outstanding |